Development and Validation of a Rapid Point-of-CCare Diagnostic for Sickle Cell Disease Using Microfluidic Erythrocyte Deformation Profiling

Project Abstract

This study presents the development and validation of a rapid point-of-care diagnostic platform that leverages microfluidic erythrocyte deformation profiling to detect and differentiate sickle cell disease (SCD) in clinical and field settings. The core innovation integrates a microfluidic chip with programmable shear fields to elicit erythrocyte mechanical responses that are characteristic of sickling and hemoglobinopathy-related deformability changes. By capturing high-speed video of single-cell transit through constrictions and applying advanced image analysis, we extract quantitative biomarkers including deformability index, transit time, elongation ratio, and recovery dynamics under hypoxic and normoxic conditions. A multi-parameter classifier, developed through machine learning, combines these biomarkers to distinguish between healthy individuals, sickle cell trait carriers, and patients with homozygous SCD, achieving robust discrimination even at low hematocrits and across varied sample types (venous blood, capillary finger-prick specimens). Analytical validation demonstrates high sensitivity and specificity, with receiver operating characteristic (ROC) curves yielding area under the curve (AUC) values exceeding 0.95 for HbSS and HbAS discrimination in blinded tests. The platform requires minimal sample preparation within 15–20 minutes, and the integrated reader provides real-time results within 5–10 minutes post-sampling, making it suitable for point-of-care decision-making in rural clinics, emergency departments, and screening programs. Reproducibility studies indicate inter-device and inter-operator consistency with coefficients of variation below 8% for key deformability metrics. The technology also shows resilience to pre-analytical variables such as sample aging, temperature fluctuations, and minor hemolysis, leveraging normalization strategies against physiological baselines. Clinical performance is evaluated across a diverse cohort that includes pediatric and adult populations from multiple geographic regions with pronounced SCD prevalence. We address potential confounders, including coexistent hemoglobinopathies and infectious conditions, by incorporating a broad reference spectrum and implementing a hierarchical classification framework. The microfluidic platform is designed for manufacturability and low-cost operation, with components fabricated from biocompatible polymers and modular optics enabling scalable production and straightforward maintenance. An end-to-end workflow is demonstrated, from sample collection and loading to automated image capture, feature extraction, and on-device or cloud-based analytics, ensuring data traceability and secure patient information handling. In addition to diagnostic capability, the study explores clinical utility metrics such as time-to-diagnosis, impact on triage efficiency, and potential integration with newborn screening paradigms and longitudinal disease monitoring. The work lays the foundation for broader application of microfluidic deformability profiling in hemoglobinopathy diagnostics and paves the way for rapid, accessible, and accurate SCD testing in resource-limited settings, with implications for improved patient outcomes through timely intervention and tailored management.

Project Overview

What This Project Is About

---

A plain-language overview of the topic and what the project investigates.

---

---

The Problem It Addresses

---

What problem or gap this project tackles and why it matters to the field or society.

---

---

Objectives of the Project

---

1. Describe the main goal: to develop a fast, point-of-care test for sickle cell disease using a microfluidic method.
2. Show how the test separates and analyzes red blood cells to detect sickling tendencies quickly.
3. Validate the test against standard laboratory methods to ensure accuracy.
4. Assess usability, cost, and how results can be read by non-specialists.
5. Identify limitations and propose improvements for real-world use.

---

---

What You Will Do Step by Step

---

1. Learn basic sickle cell biology and how microfluidics works in simple terms.
2. Design or adopt a microfluidic chip to profile red blood cell deformation.
3. Collect blood samples (with appropriate ethics approval) and run the chip tests.
4. Compare results with standard tests to measure accuracy.
5. Analyze data to determine sensitivity and specificity.
6. Evaluate practical aspects: speed, cost, and ease of use.
7. Document procedures, results, and possible improvements.

---

---

Expected Outcome

1. A validated, rapid, point-of-care diagnostic approach for sickle cell disease based on cell deformation profiles.
2. Evidence of accuracy comparable to conventional tests, plus insights into practical deployment.